Lytix Biopharma AS reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was NOK 3.92 million compared to NOK 1.41 million a year ago. Revenue was NOK 4.29 million compared to NOK 2.97 million a year ago. Net loss was NOK 18.25 million compared to NOK 11.15 million a year ago.
For the nine months, sales was NOK 3.99 million compared to NOK 1.41 million a year ago. Revenue was NOK 5.12 million compared to NOK 15.66 million a year ago. Net loss was NOK 69.36 million compared to NOK 26.81 million a year ago.